Annals of Clinical Microbiology and Antimicrobials, published by BMC, is a leading open-access journal that has been fostering scientific discourse in the fields of microbiology and infectious diseases since its inception in 2002. With an established reputation for excellence, this journal is positioned in the prestigious Q1 category across multiple disciplines, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology as of 2023. This journal serves as a vital platform for researchers, healthcare professionals, and students, promoting the latest advancements in clinical microbiology and antimicrobial research. Access to its invaluable content is open to all, reflecting the commitment to disseminate knowledge universally. The Annals of Clinical Microbiology and Antimicrobials is based in the United Kingdom and continues to pave the way for innovation and discussions that shape the future of clinical practices in microbiology.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, published by ELSEVIER SCI LTD, stands as a leading platform in the realm of infectious diseases, contributing significantly to the global understanding of this critical field. With an impressive impact factor, the journal maintains a distinguished Q1 ranking across various categories, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, demonstrating its high relevance and influence among contemporary research. Since its inception in 1996, it has embraced an Open Access model, allowing for wider dissemination of essential research findings that can inform public health policies and clinical practices. With a commitment to advancing scientific knowledge, this journal is not only a vital resource for researchers and professionals but also serves as an invaluable educational tool for students interested in the complexities of infectious diseases and their management. For those looking to stay at the forefront of research and innovation in this field, the INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES is an indispensable resource.

Travel Medicine and Infectious Disease is a premier peer-reviewed journal published by Elsevier Science Ltd, dedicated to advancing the field of travel medicine and infectious disease research. With an impressive impact factor and a category ranking of Q1 in both Infectious Diseases and Public Health, Environmental and Occupational Health, this journal is recognized as a leading source of high-quality research and insights. Originating in 2003 and transitioning to an Open Access model in 2023, it aims to disseminate critical findings that enhance the understanding of health risks associated with travel, vaccination strategies, and infectious disease outbreaks. The journal’s Scopus rankings reflect its influence, with a rank of 7/665 in Public Health and 20/344 in Infectious Diseases. Researchers, healthcare professionals, and students will find this journal invaluable for staying informed on the latest trends and developments in travel-related health challenges.

The Canadian Journal of Infectious Diseases & Medical Microbiology, published by HINDAWI LTD, is a pioneering open-access journal focused on advancing the fields of infectious diseases and medical microbiology, with its commitment to disseminating innovative research since 2004. With the ISSN 1712-9532 and E-ISSN 1918-1493, the journal is recognized for its high-caliber contributions, achieving a 2023 Q2 ranking in Infectious Diseases and a Q3 ranking in Medical Microbiology, as per the prestigious Scopus rankings. Offering a global platform for researchers and clinicians, the journal is crucial for fostering collaboration and sharing knowledge across borders, emphasizing its role as a significant resource for addressing pressing health challenges. With an HIndex that indicates an increasing influence in the scientific community, the journal maintains its focus on impactful studies that inform clinical practices and policies, while also being available to a diverse audience through its open-access format. Based in Egypt, the journal looks forward to continuing its impact up to 2024 and beyond, serving as a vital forum for scientific exchange and practical applications in the fight against infectious diseases.

LANCET INFECTIOUS DISEASES is a premier journal published by Elsevier Science Ltd, dedicated to disseminating high-quality research and comprehensive reviews in the field of infectious diseases. Since its inception in 2001, the journal has become a pivotal resource in the medical community, recognized for its rigorous peer-review process and impactful contributions to public health. With an impressive Scopus rank of #2 out of 344 in the category of Medicine - Infectious Diseases, it consistently ranks in the 99th percentile, highlighting its importance and influence in shaping clinical and epidemiological research. The journal's commitment to advancing knowledge in infectious diseases is underscored by its Q1 quartile designation in 2023, affirming its status as a leading academic outlet. Although not an open-access journal, LANCET INFECTIOUS DISEASES provides essential insights for researchers, healthcare professionals, and students, bridging the gap between cutting-edge research and practical application in an increasingly interconnected world.

Current Treatment Options in Infectious Diseases, published by SpringerNature, is a pivotal peer-reviewed journal dedicated to advancing the field of infectious disease management and therapy. With a focus on the latest treatment modalities, this journal serves as a vital resource for researchers, healthcare professionals, and students striving to improve patient outcomes in infectious diseases. Although it is not an open-access journal, it offers valuable insights through carefully curated articles that emphasize evidence-based practices and innovative approaches in the treatment landscape. By fostering a cross-disciplinary dialogue, Current Treatment Options in Infectious Diseases aims to bridge the gap between research and clinical application, making it an essential platform for staying abreast of developments in this rapidly evolving field.

Journal of Infection in Developing Countries, published by J INFECTION DEVELOPING COUNTRIES, is a premier open-access journal dedicated to advancing research in the fields of infectious diseases, microbiology, parasitology, and virology, particularly within the context of developing nations. Established in 2007 and actively disseminating knowledge since 2008, this journal aims to bridge the gap between researchers and practitioners by providing a platform for high-quality, peer-reviewed articles that address the unique challenges faced in these regions. With an ISSN of 1972-2680 and a robust HIndex showcasing its growing influence, JIDC has attained a Q3 category ranking in several disciplines as of 2023, indicating its crucial role in shaping ongoing discourse in public health. As an open-access publication, it ensures that vital research is accessible to all, fostering collaboration and innovation in infectious disease management and control.

Journal of Pediatric Infection is a vital academic resource dedicated to the ever-evolving field of infectious diseases in pediatric populations. Published by AVES YAYINCILIK in Turkey, this journal features a rigorous peer-review process and has established itself as a platform for innovative research from around the globe. Although currently categorized in the Q4 quartile for both Infectious Diseases and Pediatrics, Perinatology and Child Health, the journal's potential for growth is substantial, attracting contributions that aim to shed light on the complexities of infectious diseases affecting children. With a converged publication history from 2009 to 2024, the journal emphasizes the importance of advancing knowledge in pediatric health through systematic reviews, original research, and case studies. Its open access policy encourages unrestricted sharing of vital research findings, making it an essential read for researchers, clinicians, and students dedicated to improving pediatric healthcare outcomes.

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

International Journal of Mycobacteriology is a peer-reviewed, open-access journal published by Wolters Kluwer Medknow Publications that specializes in the field of infectious diseases with a particular emphasis on mycobacterial research. Since its inception in 2012, this journal has emerged as a vital resource for researchers, healthcare professionals, and students aimed at advancing understanding and treatment of mycobacterial infections, including tuberculosis. With the journal being indexed in Scopus and holding a Q3 ranking in both Infectious Diseases and Microbiology (medical) for 2023, it reflects a substantial contribution to scholarly discourse in these domains, despite its current ranking positioning. Authors and readers benefit from the open access model, ensuring widespread dissemination of research findings and fostering collaboration across the global health community. Located in Mumbai, India, the journal continues to thrive with a commitment to quality research and innovation, welcoming contributions that further the exploration of mycobacteriology throughout the converged years from 2012 to 2024.